Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.59 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | PTPRB | P23467 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29098487 | 0.88 | KMT2A (0.56) | MEN1KMT2AGPR119USP30 | |
| SCHEMBL27391167 | 0.88 | MEN1 (0.53) | MEN1KMT2AGPR119USP30 | |
| SCHEMBL3837667 | 0.88 | MEN1 (0.61) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL25391302 | 0.87 | MEN1 (0.67) | MEN1KMT2AGPR119USP30STS | |
| SCHEMBL16422601 | 0.87 | MEN1 (0.67) | MEN1KMT2AGPR119USP30 | |
| SCHEMBL18319317 | 0.87 | MEN1 (0.52) | MEN1KMT2AGPR119USP30 | |
| SCHEMBL27091311 | 0.86 | USP30 (0.54) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL22462921 | 0.86 | MEN1 (0.54) | MEN1KMT2AGPR119USP30STS | |
| SCHEMBL8333913 | 0.85 | MEN1 (0.68) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL25967727 | 0.85 | MEN1 (0.51) | MEN1KMT2AGPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1847530-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | MEN1 3396/4885KMT2A 441/4885GPR119 1988/4885 |
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | PDF, PEPD, DPEP1 | MEN1 2365/4885KMT2A 2750/4885GPR119 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.